- Home
- NCZ vs ALDX Comparison
NCZ vs ALDX Comparison
Compare NCZ & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCZ | ALDX |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | United States | US |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.3M | 317.7M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | NCZ | ALDX |
|---|---|---|
| Price | $14.90 | $4.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 65.6K | ★ 723.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 12.16% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $36.25 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.23 | $1.18 |
| 52 Week High | $14.99 | $7.19 |
Technical Indicators
Market Signals| Indicator | NCZ | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 64.23 | 45.80 |
| Support Level | $14.71 | $5.04 |
| Resistance Level | $14.93 | $5.56 |
| Average True Range (ATR) | 0.21 | 0.35 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 81.83 | 6.37 |
Price Performance
Historical ComparisonAbout NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. The investment objective of the company is to provide total return through a combination of capital appreciation and high current income. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas, and consumable fuels and others.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.